We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

46 hedge funds and large institutions have $284M invested in Aclaris Therapeutics in 2016 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 2

380% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 5

35% more funds holding

Funds holding: 34 → 46 (+12)

3% more capital invested

Capital invested by funds: $276M → $284M (+$7.68M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
46
Holders Change
+12
Holders Change %
+35.29%
% of All Funds
1.23%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
14
Increased
24
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Fidelity International
Fidelity International
Bermuda
+$14.8M
2
CAM
Cormorant Asset Management
Massachusetts
+$5.02M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$4.95M
4
RSCM
Rock Springs Capital Management
Maryland
+$2.07M
5
BFA
BlackRock Fund Advisors
California
+$1.74M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$20.1M
2
TI
Turner Investments
Pennsylvania
-$1.65M
3
Franklin Resources
Franklin Resources
California
-$1.28M
4
OM
Opaleye Management
Massachusetts
-$341K
5
Citigroup
Citigroup
New York
-$149K
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
1
Vivo Capital
California
$77.4M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$51.5M -$20.1M -1,014,381 -27%
RCM
3
RA Capital Management
Massachusetts
$48.5M – – –
Franklin Resources
4
Franklin Resources
California
$29.1M -$1.28M -64,570 -4%
RSCM
5
Rock Springs Capital Management
Maryland
$18.5M +$2.07M +104,500 +12%
CAM
6
Cormorant Asset Management
Massachusetts
$16.6M +$5.02M +253,342 +39%
Fidelity International
7
Fidelity International
Bermuda
$13.8M +$14.8M +747,205 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$7.74M +$4.95M +249,888 +148%
BFA
9
BlackRock Fund Advisors
California
$4.33M +$1.74M +87,739 +60%
State Street
10
State Street
Massachusetts
$2.22M +$935K +47,179 +65%
Northern Trust
11
Northern Trust
Illinois
$1.4M +$364K +18,357 +32%
BIT
12
BlackRock Institutional Trust
California
$1.31M +$845K +42,644 +151%
MIM
13
Monashee Investment Management
Massachusetts
$1.11M – – –
HighTower Advisors
14
HighTower Advisors
Illinois
$959K +$1.03M +51,886 New
Norges Bank
15
Norges Bank
Norway
$924K – – –
Geode Capital Management
16
Geode Capital Management
Massachusetts
$905K +$115K +5,779 +13%
Deutsche Bank
17
Deutsche Bank
Germany
$671K +$704K +35,513 +4,110%
EI
18
EAM Investors
California
$668K +$716K +36,142 New
Bank of New York Mellon
19
Bank of New York Mellon
New York
$652K +$391K +19,734 +127%
BIM
20
BlackRock Investment Management
Delaware
$631K +$272K +13,734 +67%
TC
21
TFS Capital
Pennsylvania
$614K +$658K +33,223 New
TCIM
22
TIAA CREF Investment Management
New York
$525K +$307K +15,487 +120%
EA
23
Emerald Acquisition
Washington
$500K +$537K +27,096 New
Charles Schwab
24
Charles Schwab
California
$439K +$136K +6,852 +41%
California State Teachers Retirement System (CalSTRS)
25
California State Teachers Retirement System (CalSTRS)
California
$349K +$132K +6,683 +55%
1
2

ACRS Hedge Fund Activity: Q2 2016 in Review

46 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q2 2016, worth a combined $284M — up 2.8% from $276M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new ACRS positions and 2 closed out — a net gain of 12 holders — while 24 added to existing stakes and 5 trimmed.

The largest buyer was Fidelity International, opening a new position worth an estimated $14.8M. The largest seller was Fidelity Investments, cutting an estimated $20.1M.

  • 46 institutional investors held Aclaris Therapeutics (ACRS) as of Q2 2016, up from 34 in Q1 2016.
  • Funds reported $284M of Aclaris Therapeutics stock for Q2 2016, up 2.8% quarter-over-quarter.
  • 14 funds opened new Aclaris Therapeutics positions in Q2 2016 and 2 closed out, a net change of +12 holders.
  • The largest Aclaris Therapeutics buyer in Q2 2016 was Fidelity International, an estimated $14.8M added.
  • The largest Aclaris Therapeutics seller in Q2 2016 was Fidelity Investments, an estimated $20.1M sold.

Based on aggregated 13F filings for Q2 2016.